Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
0.910
+0.010 (1.11%)
Mar 30, 2023, 1:00 PM EDT - Market open
1.11%
Market Cap 47.30M
Revenue (ttm) n/a
Net Income (ttm) -22.66M
Shares Out 51.97M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,106
Open 0.935
Previous Close 0.900
Day's Range 0.882 - 0.935
52-Week Range 0.736 - 2.670
Beta -0.37
Analysts Buy
Price Target 5.44 (+497.8%)
Earnings Date Mar 29, 2023

About GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2018
Employees 22
Stock Exchange NASDAQ
Ticker Symbol GNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for GNPX stock is "Buy." The 12-month stock price forecast is $5.44, which is an increase of 497.80% from the latest price.

Price Target
$5.44
(497.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options AUSTIN, Texas , March 23, 2023 /PRNewswire/ -- Rodney ...

1 week ago - PRNewsWire

Genprex to Present at Bioprocessing Summit Conference

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:...

2 weeks ago - PRNewsWire

Genprex to Participate in March Investor and Industry Conferences

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes AUSTIN, Texas , March 8, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stag...

3 weeks ago - PRNewsWire

Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

AUSTIN, Texas , Feb. 27, 2023 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...

1 month ago - PRNewsWire

Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data

Genprex (NASDAQ: GNPX) stock is on the move Thursday after providing an update on a study of its diabetes treatment. That positive news comes from a trial of gene therapy for the treatment of Type 1 ...

1 month ago - InvestorPlace

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline Disruptive gene therapy approach deve...

1 month ago - PRNewsWire

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Typ...

3 months ago - PRNewsWire

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex's Gene Therapy Program in Diabetes to be Showcased AUSTIN, Texas , Jan. 4, 2023 /PRNewswire/ -- Gen...

3 months ago - PRNewsWire

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-st...

3 months ago - PRNewsWire

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas , Dec. 14...

3 months ago - PRNewsWire

Genprex to Present at Upcoming December Investor Conference

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinica...

4 months ago - PRNewsWire

Genprex to Present at Upcoming October Investor and Industry Conferences

Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX...

6 months ago - PRNewsWire

Genprex to Present at Upcoming September Investor Conference

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 8, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinic...

7 months ago - PRNewsWire

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

Provides Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial AUSTIN, Texas , Aug. 16, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clini...

8 months ago - PRNewsWire

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial AUSTIN, Texas , Aug. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

8 months ago - PRNewsWire

Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems AUSTIN, Texas , July 13, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Compa...

9 months ago - PRNewsWire

Genprex to Present at Upcoming June Investor Conferences

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , June 2, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical...

10 months ago - PRNewsWire

Genprex to Present at Upcoming Investor Conference in May 2022

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinica...

11 months ago - PRNewsWire

Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors AUSTIN, Texas , May 9, 2022 /PRNewswire/ -- Genpr...

11 months ago - PRNewsWire

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" ...

11 months ago - PRNewsWire

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas , April 18, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-s...

1 year ago - PRNewsWire

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces it has opened its Acclaim-2 clinical trial for patient enrollment.

1 year ago - Business Wire

Genprex to Participate in Upcoming Investor Conference in March

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in March conferences.

1 year ago - Business Wire

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces the dosing of its first patient in its Acclaim-1 clinical trial in non-small cell lung cancer

1 year ago - Business Wire

Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in February conferences.

1 year ago - Business Wire